A 6-Week Randomized, Placebo-Controlled Trial of CP-316,311 (a Selective CRH 1 Antagonist) in the Treatment of Major Depression
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The corticotropin-releasing hormone (CRH) system is implicated in the pathogenesis of several psychiatric disorders, including major depressive disorder. This study was designed to evaluate the safety and efficacy of CP-316,311, a selective nonpeptide antagonist of corticotropin-releasing hormone type 1 (CRH(1)) receptors, in the treatment of recurrent major depressive disorder. METHOD: Of a total of 167 patients with recurrent major depression who were screened, 123 were randomly assigned to receive 400 mg of CP-316,311 twice daily, or 100 mg of sertraline daily, or placebo in a 6-week fixed-dose, double-blind, double-dummy, parallel-group, placebo- and sertraline-controlled trial. The primary efficacy analysis compared the change in score from baseline to endpoint on the 17-item Hamilton Depression Rating Scale (HAM-D) between the CP-316,311 and placebo groups. A group sequential design was used to support early trial termination based on efficacy or futility at a planned interim analysis. RESULTS: The evaluable data set for the interim analysis included 28 patients in the CP-316,311 group, 31 patients in the placebo group, and 30 patients in the sertraline group. In the interim analysis, the change from baseline in the HAM-D score at the final visit was not significantly different between the CP-316,311 and placebo groups, while change from baseline between the sertraline and placebo groups was significantly different. Given these results, futility was declared for CP-316,311 and the trial was terminated. CONCLUSIONS: Although CP-316,311 was safe and well tolerated in this study population, it failed to demonstrate efficacy in the treatment of major depression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another CRH1 receptor antagonist, CP-316,311, could not achieve a significant improvement of depressive symptoms compared to placebo [102].”
From The HPA Axis as Target for Depression (2024) · cites this paper as [102]
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310 · cited 3×
“tral administration of alpha helical CRH-(9-41), a specific CRH receptor antagonist (4).”
BackgroundMethodDiscrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
The role of corticotropin-releasing factor in depression and anxiety disorders
Arborelius, L., Owens, M., Plotsky, P., & Nemeroff, C. (1999) · Journal of Endocrinology · doi:10.1677/joe.0.1600001 · Cited by 1,378
Physiology and pharmacology of corticotropin-releasing factor.
Owens, M. J., & Nemeroff, C. B. (1991) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06673-6 · Cited by 1,142
Zobel, A. W., Nickel, T., Künzel, H. E., Ackl, N., Sonntag, A., Ising, M., & Holsboer, F. (2000) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(00)00016-9 · Cited by 705
Reduced Corticotropin Releasing Factor Binding Sites in the Frontal Cortex of Suicide Victims
Nemeroff, C. B. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800300075009 · Cited by 555
The Dexamethasone Suppression Test for Diagnosis and Prognosis in Psychiatry: Commentary and Review
Arana, G. W. (1985) · Archives of General Psychiatry · doi:10.1001/archpsyc.1985.01790350067012 · Cited by 526
Adrenal Gland Enlargement in Major Depression: A Computed Tomographic Study
Nemeroff, C. B. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820050048008 · Cited by 283
Nemeroff, C. B., Bissette, G., Akil, H., & Fink, M. (1991) · British Journal of Psychiatry · doi:10.1192/bjp.158.1.59 · Cited by 254
Research works printed but not linked: 2
- Owens MJ, 1991, Pharmacol Rev, 43, 425
- Shelton RC, 1994, Clin Ther, 16, 768
Cited by
Stetler, C., & Miller, G. E. (2011) · Psychosomatic Medicine · doi:10.1097/psy.0b013e31820ad12b · Cited by 1,123
“Although this result is based on a limited number of studies and should be interpreted with caution, it is markedly divergent from the widely accepted idea that depression is associated with CRH hypersecretion (12).”
ResultNeurobiological and psychiatric consequences of child abuse and neglect
Heim, C., Shugart, M., Craighead, W. E., & Nemeroff, C. B. (2010) · Developmental Psychobiology · doi:10.1002/dev.20494 · Cited by 613
“A second study of another CRH receptor antagonist showed no evidence of efficacy in major depression (Binneman et al., 2008).”
BackgroundAgomelatine, the first melatonergic antidepressant: discovery, characterization and development
de Bodinat, C., Guardiola-Lemaitre, B., Mocaër, E., Renard, P., Muñoz, C., & Millan, M. J. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3140 · Cited by 593
“Unfortunately, clinical trials have been disappointin”
Stress Hormone Regulation: Biological Role and Translation into Therapy
Holsboer, F., & Ising, M. (2010) · Annual Review of Psychology · doi:10.1146/annurev.psych.093008.100321 · Cited by 473
Neurobiological mechanisms in major depressive disorder
aan het Rot, M., Mathew, S. J., & Charney, D. S. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.080697 · Cited by 470
“However, a recent study found no significant antidepressive effect of a drug with selective action on the corticotropin-releasing factor type 1 receptor.(71) In contrast, in a study that used the anesthetic ketamine, which has actions on both dopamine and glutamate, a single intravenous administration of a subanesthet…”
ResultThe CRF system, stress, depression and anxiety—insights from human genetic studies
Binder, E. B., & Nemeroff, C. B. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.141 · Cited by 379
Jakobsen, J. C., Katakam, K. K., Schou, A., Hellmuth, S. G., Stallknecht, S. E., Leth-Møller, K., Iversen, M., Banke, M. B., Petersen, I. J., Klingenberg, S. L., et al. (2017) · BMC Psychiatry · doi:10.1186/s12888-016-1173-2 · Cited by 366
Role of neuropeptides in anxiety, stress, and depression: From animals to humans
Kormos, V., & Gaszner, B. (2013) · Neuropeptides · doi:10.1016/j.npep.2013.10.014 · Cited by 329
“However, Binneman et al. (2008) in their clinical study failed to show the significant beneficial effects of the CRF1 receptor antagonist CP-316,311 (Binneman et al., 2008).”
Time to connect: bringing social context into addiction neuroscience
Heilig, M., Epstein, D. H., Nader, M. A., & Shaham, Y. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.67 · Cited by 298
The Corticotropin-Releasing Factor Family: Physiology of the Stress Response
Deussing, J. M., & Chen, A. (2018) · Physiological Reviews · doi:10.1152/physrev.00042.2017 · Cited by 260
Hormonal Treatments for Major Depressive Disorder: State of the Art
Dwyer, J. B., Aftab, A., Radhakrishnan, R., Widge, A., Rodriguez, C. I., Carpenter, L. L., Nemeroff, C. B., McDonald, W. M., Kalin, N. H., & APA Council of Research Task Force on Novel Biomarkers and Treatments (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.19080848 · Cited by 252
Pharmacogenetic approaches to the treatment of alcohol addiction
Heilig, M., Goldman, D., Berrettini, W., & O'Brien, C. P. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3110 · Cited by 248
“Compounds with better properties have since been developed, but trials that tested these compounds for use in the treatment of anxiety and depression have been disappointin”
Region-specific roles of the corticotropin-releasing factor–urocortin system in stress
Henckens, M. J. A. G., Deussing, J. M., & Chen, A. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.94 · Cited by 247
Is the HPA Axis as Target for Depression Outdated, or Is There a New Hope?
Menke, A. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00101 · Cited by 240
“A further trial using another CRH1 receptor antagonist, CP-316,311 did not observe a significant difference between patients treated with CP-316,311 and placebo (82).”
The Neurobiological Toll of Child Abuse and Neglect
Neigh, G. N., Gillespie, C. F., & Nemeroff, C. B. (2009) · Trauma, Violence, & Abuse · doi:10.1177/1524838009339758 · Cited by 240
“Although a recent clinical trial in major depression with a Pfizer compound was unsuccessful, this trial did not distinguish between individuals with and without exposure to early life stress (ELS; Binneman et al., 2008), and moreover the magnitude of CRF1 receptor occupancy obtained in this study was unclear.”
ResultEmerging mechanisms and treatments for depression beyond SSRIs and SNRIs
Dale, E., Bang-Andersen, B., & Sánchez, C. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.03.011 · Cited by 234
Role of CRF Receptor Signaling in Stress Vulnerability, Anxiety, and Depression
Hauger, R. L., Risbrough, V., Oakley, R. H., Olivares‐Reyes, J. A., & Dautzenberg, F. M. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05011.x · Cited by 217
Bosch, O. J., Nair, H. P., Ahern, T. H., Neumann, I. D., & Young, L. J. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.154 · Cited by 216
“Interestingly, there is growing evidence supporting the use of CRF-R1 antagonists as antidepressants (Holsboer, 1999; Bale, 2005; Zobel et al, 2000; but see Binneman et al, 2008).”
BackgroundBehavioral effects of neuropeptides in rodent models of depression and anxiety
Rotzinger, S., Lovejoy, D. A., & Tan, L. A. (2010) · Peptides · doi:10.1016/j.peptides.2009.12.015 · Cited by 211
Translational and reverse translational research on the role of stress in drug craving and relapse
Sinha, R., Shaham, Y., & Heilig, M. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2263-y · Cited by 208
“Assessing the drug user’s vulnerability to stress may be particularly important in future studies assessing the effect of CRF1 receptor antagonists on drug craving and relapse, because these compounds failed in double-blind phase II clinical trials of depression using non-selected patient populations (Binneman et al.…”
Millan, M. J. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2008.10.039 · Cited by 196
Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?
Griebel, G., & Holsboer, F. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3702 · Cited by 194
Coric, V., Feldman, H. H., Oren, D. A., Shekhar, A., Pultz, J., Dockens, R. C., Wu, X., Gentile, K. A., Huang, S.-P., Emison, E., et al. (2010) · Depression and Anxiety · doi:10.1002/da.20695 · Cited by 172
“There have been several other CRF1 antagonists studied by other pharmaceutical companies to date however, negative data from only one placebo-controlled study using a CRF1 antagonist in depression have been published.([26]) The absence of any beneficial effects of pexacerfont over placebo in anxiety symptoms is somewh…”
BackgroundDon’t stress about CRF: assessing the translational failures of CRF1antagonists
Spierling, S. R., & Zorrilla, E. P. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4556-2 · Cited by 170
Progress in corticotropin-releasing factor-1 antagonist development
Zorrilla, E. P., & Koob, G. F. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.02.011 · Cited by 167
“By contrast, development of ONO-2333Ms and CP-316311 were discontinued because of negative efficacy results in double-blind, placebo-controlled trials for major depression [99].”
ResultSchwandt, M. L., Cortes, C. R., Kwako, L. E., George, D. T., Momenan, R., Sinha, R., Grigoriadis, D. E., Pich, E. M., Leggio, L., & Heilig, M. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.61 · Cited by 159
“CRF1 antagonists with improved safety followed, but yielded negative results both in depression (Binneman et al, 2008) and anxiety disorders (Coric et al, 2010).”
BackgroundKwako, L. E., Spagnolo, P. A., Schwandt, M. L., Thorsell, A., George, D. T., Momenan, R., Rio, D. E., Huestis, M., Anizan, S., Concheiro, M., et al. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.306 · Cited by 158
“CRH1 antagonists with improved safety followed, but yielded negative results both in depression (Binneman et al, 2008) and anxiety disorders (Coric et al, 2010).”
BackgroundResultNew targets for rapid antidepressant action
Machado-Vieira, R., Henter, I. D., & Zarate Jr., C. A. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.12.001 · Cited by 154
Development of pharmacotherapies for drug addiction: a Rosetta stone approach
Koob, G. F., Kenneth Lloyd, G., & Mason, B. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2828 · Cited by 154
Pharmacotherapy of PTSD: premises, principles, and priorities.
Ravindran, L. N., & Stein, M. B. (2009) · Brain Research · doi:10.1016/j.brainres.2009.03.037 · Cited by 153
“…trials of these agents in PTSD to date, preliminary investigations have explored their use in major depression, albeit with only limited success (Binneman et al., 2008; Zobel et al., 2000); results have been hampered in part by reports of potential hepatotoxicity of some compounds Although…”
BackgroundHypothalamic‐Pituitary‐Adrenocortical Axis: Neuropsychiatric Aspects
Jacobson, L. (2014) · Comprehensive Physiology · doi:10.1002/cphy.c130036 · Cited by 144
“A second trial with a different non-peptide CRHR1 antagonist was discontinued because initial analysis of depression scores failed to show significant differences in patient response rates from placebo treatment (33).”
Neurobiological mechanisms of addiction: focus on corticotropin-releasing factor.
Koob, G. F., & Zorrilla, E. P. (2010) · PubMed · Cited by 169
Wong, E. H. F., Yocca, F., Smith, M. A., & Lee, C.-M. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000866 · Cited by 134
“By combining translational PK and PD measurements, it is possible to address PK/PD relationships that can help establish a valid dose range for clinical studies intended to establish efficacy (Binneman et al. 2008; Farde et al. 1988; Keller et al. 2006).”
BackgroundOtte, C., Hinkelmann, K., Moritz, S., Yassouridis, A., Jahn, H., Wiedemann, K., & Kellner, M. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2009.10.006 · Cited by 129
“, 2000) although findings are equivocal (Binneman et al., 2008).”
BackgroundThe HPA Axis as Target for Depression
Menke, A. (2024) · Current Neuropharmacology · doi:10.2174/1570159x21666230811141557 · Cited by 131
“Another CRH1 receptor antagonist, CP-316,311, could not achieve a significant improvement of depressive symptoms compared to placebo [102].”
BackgroundPharmacogenetics of antidepressants
Crisafulli, C., Fabbri, C., Porcelli, S., Drago, A., Spina, E., De Ronchi, D., & Serretti, A. (2011) · Frontiers in Pharmacology · doi:10.3389/fphar.2011.00006 · Cited by 113
Binder, E. B., Owens, M. J., Liu, W., Deveau, T. C., Rush, A. J., Trivedi, M. H., Fava, M., Bradley, B., Ressler, K. J., & Nemeroff, C. B. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.18 · Cited by 111
Zorrilla, E. P., Heilig, M., de Wit, H., & Shaham, Y. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.12.017 · Cited by 108
Open questions in current models of antidepressant action
Tanti, A., & Belzung, C. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00585.x · Cited by 109
“Effectiveness of CRF1 antagonists has also been described in some clinical studies (Holsboer and Ising, 2008) even if others failed to replicate the same findings (Binneman et al., 2008).”
ResultBrown, A. D. H., Barton, D. A., & Lambert, G. W. (2009) · CNS Drugs · doi:10.2165/00023210-200923070-00004 · Cited by 126
A role for corticotropin-releasing factor in functional gastrointestinal disorders
Taché, Y., Kiank, C., & Stengel, A. (2009) · Current Gastroenterology Reports · doi:10.1007/s11894-009-0040-4 · Cited by 109
“Ising and Holsboer [39], Binneman et al. [ 40 ], Sagami et al. [46] Anxiety (may or may not infl uence)”
BackgroundResultTranslating Across Circuits and Genetics Toward Progress in Fear- and Anxiety-Related Disorders
Ressler, K. J. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20010055 · Cited by 104
Kehne, J. H., & Cain, C. K. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.08.011 · Cited by 105
The impact of treatment on HPA axis activity in unipolar major depression
McKay, M. S., & Zakzanis, K. K. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2009.07.012 · Cited by 103
“Several CRH1 antagonists have been developed and tested with the hopes of identifying another effective treatment for depression (Holsboer and Ising, 2008) with both positive (Zobel et al., 2000) and negative clinical findings (Binneman et al., 2008).”
BackgroundFaster, better, stronger: Towards new antidepressant therapeutic strategies
O’Leary, O. F., Dinan, T. G., & Cryan, J. F. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.046 · Cited by 115
“, 2000) has been largely suspended due to lack of efficacy (Binneman et al., 2008).”
BackgroundKokras, N., Hodes, G. E., Bangasser, D. A., & Dalla, C. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14710 · Cited by 100
“CP‐ 316,311 was prematurely terminated as it lacked efficacy in 118 men and women with depression (Binneman et al., 2008).”
BackgroundHong, S., Zheng, G., Wu, X., Snider, N. T., Owyang, C., & Wiley, J. W. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.11.003 · Cited by 98
Loss of hypothalamic corticotropin-releasing hormone markedly reduces anxiety behaviors in mice
Zhang, R., Asai, M., Mahoney, C. E., Joachim, M., Shen, Y., Gunner, G., & Majzoub, J. A. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.136 · Cited by 97
Amici, M. D., Dallanoce, C., Holzgrabe, U., Tränkle, C., & Mohr, K. (2009) · Medicinal Research Reviews · doi:10.1002/med.20166 · Cited by 106
“8 nM in receptor binding and CNS oral activity in in vivo models,(229) failed to demonstrate efficacy in the treatment of MDD.(230) Further areas of potential therapeutic intervention for selective CRF1 receptor antagonists are drug abuse and irritable bowel syndrome, a stress-related gastrointestinal disorder which i…”
BackgroundInfluentialCorticotropin-Releasing Factor (CRF) circuit modulation of cognition and motivation
Hupalo, S., Bryce, C. A., Bangasser, D. A., Berridge, C. W., Valentino, R. J., & Floresco, S. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.06.010 · Cited by 103
“However, subsequent studies in subjects with major depression reported moderate, yet significant decreases in cortisol levels following 6 weeks of antagonist treatment (Binneman et al., 2008).”
BackgroundCorticotropin-releasing hormone and the hypothalamic–pituitary–adrenal axis in psychiatric disease
Naughton, M., Dinan, T. G., & Scott, L. V. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-59602-4.00005-8 · Cited by 108
Bailey, C. R., Cordell, E., Sobin, S. M., & Neumeister, A. (2013) · CNS Drugs · doi:10.1007/s40263-013-0051-4 · Cited by 89
“CRF-1 receptor antagonism is a treatment modality that has been explored for the treatment of MDD [166], while an initial open-label study suggested promising efficacy data, these results were not confirmed in follow-up placebo-controlled trials [167].”
ResultApplication of antidepressants in depression: A systematic review and meta-analysis
Yuan, Z., Chen, Z., Xue, M., Zhang, J., & Leng, L. (2020) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2020.08.013 · Cited by 94
Wilkinson, P. O., & Goodyer, I. M. (2011) · Development and Psychopathology · doi:10.1017/s0954579411000472 · Cited by 86
The pharmacological properties of antidepressants
Racagni, G., & Popoli, M. (2010) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283311acd · Cited by 83
“Unfortunately, clinical findings with antagonists at these sites,for example, CP-316,311, have recently proven disappointing (Binneman et al., 2008).”
BackgroundKalin, N. H., Fox, A. S., Kovner, R., Riedel, M. K., Fekete, E. M., Roseboom, P. H., Tromp, D. P. M., Grabow, B. P., Olsen, M. E., Brodsky, E. K., et al. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.01.010 · Cited by 77
Todorovic, C., Sherrin, T., Pitts, M., Hippel, C., Rayner, M., & Spiess, J. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.178 · Cited by 76
“…enhanced central CRF/CRF1 signaling contributes to the pathophysiology of major depression was recently questioned, after clinical trials employing small molecule CRF1 receptor antagonists in patients with major depression yielded inconsistent results (Zobel et al, 2000; Binneman et al., 2008).”
BackgroundResultInfluentialWong, E. H. F., Tarazi, F. I., & Shahid, M. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.02.001 · Cited by 82
“Thismode of drug discovery has led to the generation of some highly selective and system defining tool molecules such as the serotonin reuptake inhibitor fluoxetine (Fuller et al., 1991), the norepinephrine reuptake inhibitor reboxetine (Wong et al., 2000), the 5-HT1A antagonist WAY-100635 (Forster et al., 1995), the…”
BackgroundThe CRF system as a therapeutic target for neuropsychiatric disorders
Sanders, J., & Nemeroff, C. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.09.004 · Cited by 72
“CP-316,311 treated patients, however, did not differ in their HAMD change scores compared to placebo treated controls [49] (Table 1).”
BackgroundResultSchüle, C., Baghai, T. C., Eser, D., & Rupprecht, R. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.52 · Cited by 73
Pietrzak, R. H., Naganawa, M., Huang, Y., Corsi-Travali, S., Zheng, M.-Q., Stein, M. B., Henry, S., Lim, K., Ropchan, J., Lin, S.-F., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1221 · Cited by 71
RetractedEmerging targets for antidepressant therapies
Rakofsky, J. J., Holtzheimer, P. E., & Nemeroff, C. B. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.04.617 · Cited by 72
“CP-316 311, another CRF1 receptor antagonist, did not show significant antidepressant effects in a placebo-controlled and sertraline-controlled trial [63]; however, it is unclear whether the dose tested was sufficient to block CNS CRF1 receptors effectively.”
BackgroundChopra, K., & Arora, V. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.855720 · Cited by 71
“2 Nonbiogenic amine-based therapeutic strategies Although there is a formidable body of preclinical and clinical data strengthening the association between pain--depression symptomatology and alterations in aminergic transmission, both the modest remission rates (estimated at 25 -- 30%) and significant proportion (est…”
BackgroundThe amygdala, a relay station for switching on and off pain
Rouwette, T., Vanelderen, P., Roubos, E. W., Kozicz, T., & Vissers, K. (2012) · European Journal of Pain · doi:10.1002/j.1532-2149.2011.00071.x · Cited by 70
Smith, C. M., Walker, A. W., Hosken, I. T., Chua, B. E., Zhang, C., Haidar, M., & Gundlach, A. L. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00046 · Cited by 71
“CRF receptor-1 antagonists are also yet to demonstrate clear antidepressant properties (Binneman et al., 2008), although anxiolytic effects are promising (Bailey et al., 2011); and trials of these compounds against alcohol abuse and relapse are being undertaken (Zorrilla et al., 2013).”
BackgroundTen Points to Improve Reproducibility and Translation of Animal Research
Spanagel, R. (2022) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2022.869511 · Cited by 79
Brett Lloyd, R., & B. Nemeroff, C. (2011) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026611109060609 · Cited by 67
“At the interim analysis, there was no difference between placebo and CP-316,311, with a significant reduction in depression symptom severity scores in the sertraline group [78].”
BackgroundSoria, V., González-Rodríguez, A., Huerta-Ramos, E., Usall, J., Cobo, J., Bioque, M., Barbero, J. D., García-Rizo, C., Tost, M., Monreal, J. A., et al. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.04.012 · Cited by 64
Fleck, B. A., Hoare, S. R. J., Pick, R. R., BRADBURY, M. J., & Grigoriadis, D. E. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.188714 · Cited by 67
“Collectively, these findings demonstrate receptor binding kinetics provide new dimensions for understanding and potentially advancing the pharmacology of CRF1 receptor antagonists.”
BackgroundSalimando, G. J., Hyun, M., Boyt, K. M., & Winder, D. G. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.0270-20.2020 · Cited by 67
“Considering the unique biophysical properties of GluN2D-NMDARs and their restricted expression in the adult brain, our findings here suggest that the manipulation of these receptors may avoid the undesirable side effects of current treatments aimed at both the glutamate and CRF signaling systems in affective disorders…”
BackgroundStress Response Modulation Underlying the Psychobiology of Resilience
Averill, L. A., Averill, C. L., Kelmendi, B., Abdallah, C. G., & Southwick, S. M. (2018) · Current Psychiatry Reports · doi:10.1007/s11920-018-0887-x · Cited by 67
Corticotropin releasing factor receptor antagonists for major depressive disorder
Paez-Pereda, M., Hausch, F., & Holsboer, F. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.565330 · Cited by 58
“The CRF1a splice variant is primarily found in the CNS, whereas the CRF1b receptor subtype is expressed in both the brain and the periphery.”
BackgroundInfluentialHennessy, M. B., Deak, T., & Schiml-Webb, P. A. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.03.012 · Cited by 59
“…a unifying mechanism for “stress diathesis” models for the development of depressive illness (Gold et al., 1988; Heim & Nemeroff, 2001), and has helped build a case for current attempts to develop CRF antagonists as anti-depressants (Binneman et al., 2008; Holsboer & Ising, 2008; Valdez, 2006).”
Gilligan, P. J., Clarke, T., He, L., Lelas, S., Li, Y.-W., Heman, K. L., Fitzgerald, L. W., Miller, K. J., Zhang, G., Marshall, A. P., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900025h · Cited by 61
Update on GPCR-based targets for the development of novel antidepressants
Mantas, I., Saarinen, M., Xu, Q., & Svenningsson, P. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01040-1 · Cited by 61
Hartz, R. A., Ahuja, V. T., Zhuo, X., Mattson, R. J., Denhart, D. J., Deskus, J. A., Vrudhula, V. M., Pan, S., Ditta, J. L., Shu, Y., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900716v · Cited by 61
Laryea, G., Arnett, M. G., & Muglia, L. J. (2012) · Behavioral Sciences · doi:10.3390/bs2020135 · Cited by 57
Bailey, J. E., Papadopoulos, A., Diaper, A., Phillips, S., Schmidt, M., van der Ark, P., Dourish, C. T., Dawson, G. R., & Nutt, D. J. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111400650 · Cited by 55
“…studies, particularly in the treatment of anxiety and depression (Ising and Holsboer, 2007), although this evidence is not consistent, with a recent report showing lack of efficacy of a different antagonist in major depression (Binneman et al., 2008) and more recently in GAD (Coric et al., 2010).”
ResultPathogenic involvement of neuropeptides in anxiety and depression
Alldredge, B. (2010) · Neuropeptides · doi:10.1016/j.npep.2009.12.014 · Cited by 63
“Even though there is a vast body of compelling evidence indicating CRF in the pathogenesis of anxiety and depression (summarized in Table 1), clinical trials have yielded confounding results (Binneman et al., 2008).”
BackgroundChávez-Castillo, M., Núñez, V., Nava, M., Ortega, Á., Rojas, M., Bermúdez, V., & Rojas, J. (2019) · Advances in Pharmacological Sciences · doi:10.1155/2019/7943481 · Cited by 72
“In contrast, CP-316,311, a selective nonpeptide CHRH1 antagonist, has failed to show efficacy in the treatment of MDD, despite being well-tolerated [130].”
BackgroundLembke, A., Gomez, R., Tenakoon, L., Keller, J., Cohen, G., Williams, G. H., Kraemer, F. B., & Schatzberg, A. F. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.05.006 · Cited by 53
Neurobiology of alcohol seeking behavior
Domi, E., Domi, A., Adermark, L., Heilig, M. A., & Augier, E. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15343 · Cited by 63
“Combined with the failures of CRH1 antagonists on multiple other stress-related psychiatric indications (Binneman et al., 2008; Coric et al., 2010; Dunlop et al., 2017), and their termination in clinical development, it is in our view unlikely that this mechanism can be resurrected for treatment of…”
The Role of Neuropeptides in Suicidal Behavior: A Systematic Review
Serafini, G., Pompili, M., Lindqvist, D., Dwivedi, Y., & Girardi, P. (2013) · BioMed Research International · doi:10.1155/2013/687575 · Cited by 49
“Overall, there is a large body of evidence suggesting the involvement of CRF in the pathophysiology of major affective disorders [50–53] but not all studies replicated these findings [54].”
Grigoriadis, D. E., Hoare, S. R. J., Lechner, S. M., Slee, D. H., & Williams, J. A. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.149 · Cited by 52
“Although Pfizer has just recently published that CP-316,311 failed in a major depression clinical trial (Binneman et al, 2008), Pexacerfont from Bristol-Myers Squibb has currently completed three independent phase II/ III clinical trials for the potential treatment of generalized anxiety disorder…”
BackgroundCasello, S. M., Flores, R. J., Yarur, H. E., Wang, H., Awanyai, M., Arenivar, M. A., Jaime-Lara, R. B., Bravo-Rivera, H., & Tejeda, H. A. (2022) · Frontiers in Neural Circuits · doi:10.3389/fncir.2022.796443 · Cited by 55
Moussaieff, A., Gross, M., Nesher, E., Tikhonov, T., Yadid, G., & Pinhasov, A. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112458729 · Cited by 49
“However, the difficulties encountered recently in the development of antidepressants working by antagonism of CRF, GR and MR receptors (Binneman et al., 2008; Coric et al., 2010) suggest that antidepressants’ action may be affected upstream of glucocorticoid levels per se.”
BackgroundGabapentin-Induced Delirium and Dependence
Kruszewski, S. P., Paczynski, R. P., & Kahn, D. A. (2009) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000358318.73684.df · Cited by 47
The CRH1 Antagonist GSK561679 Increases Human Fear But Not Anxiety as Assessed by Startle
Grillon, C., Hale, E., Lieberman, L., Davis, A., Pine, D. S., & Ernst, M. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.316 · Cited by 49
Vandael, D., & Gounko, N. V. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0581-8 · Cited by 47
Dong, H., Wang, S., Zeng, Z., Li, F., Montalvo-Ortiz, J., Tucker, C., Akhtar, S., Shi, J., Meltzer, H. Y., Rice, K. C., et al. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3629-8 · Cited by 42
The Need for Treatment Responsive Translational Biomarkers in Alcoholism Research
Heilig, M. A., Sommer, W. H., & Spanagel, R. (2015) · Current topics in behavioral neurosciences · doi:10.1007/7854_2015_5006 · Cited by 48
Mitochondria: A Connecting Link in the Major Depressive Disorder Jigsaw
Sharma, S., & Akundi, R. S. (2018) · Current Neuropharmacology · doi:10.2174/1570159x16666180302120322 · Cited by 46
“CRF receptor antagonist, CP-316,311, was even tested in a small trial involving MDD patients but failed in its efficacy [35].”
BackgroundPost-traumatic stress disorder: emerging concepts of pharmacotherapy
Baker, D. G., Nievergelt, C. M., & Risbrough, V. B. (2009) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210902972494 · Cited by 40
“Although early, small clinical trials [185] were promising, more recent double-blind placebo-controlled studies for depression have been negative [186].”
ResultHartz, R. A., Ahuja, V. T., Rafalski, M., Schmitz, W. D., Brenner, A. B., Denhart, D. J., Ditta, J. L., Deskus, J. A., Yue, E. W., Arvanitis, A. G., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900302q · Cited by 43
Biomarkers in development of psychotropic drugs
Wiedemann, K. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.2/kwiedemann · Cited by 37
Kojima, T., Mochizuki, M., Takai, T., Hoashi, Y., Morimoto, S., Seto, M., Nakamura, M., Kobayashi, K., Sako, Y., Tanaka, M., et al. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.01.020 · Cited by 38
Novel targets for antidepressant therapies
Holtzheimer, P. E., & Nemeroff, C. B. (2008) · Current Psychiatry Reports · doi:10.1007/s11920-008-0075-5 · Cited by 37
“Another CRF 1 receptor antagonist (CP-316311; Pfi zer, Groton, CT) failed to show signifi cant antidepressant effects in a placebo- and sertraline-controlled trial [ 25 ]; whether the dose tested was suffi cient to block central nervous system CRF 1 receptors remains unclear.”
BackgroundTakahashi, Y., Hibi, S., Hoshino, Y., Kikuchi, K., Shin, K., Murata-Tai, K., Fujisawa, M., Ino, M., Shibata, H., & Yonaga, M. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300259r · Cited by 36
Morabbi, M.-J., Razaghi, E., Moazen-Zadeh, E., Safi-Aghdam, H., Zarrindast, M. R., Vousoghi, N., & Akhondzadeh, S. (2018) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000200 · Cited by 32
Corticotropin-Releasing Factor (CRF) Neurocircuitry and Neuropharmacology in Alcohol Drinking
Schreiber, A. L., & Gilpin, N. W. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2017_86 · Cited by 40
“Other small molecule CRFR1 antagonists have been tested in depression, anxiety, human fear lab studies, and PTSD but all have yielded negative results (Binneman et al. 2008; Coric et al. 2010; Dunlop et al. 2017; Grillon et al. 2015).”
Background
Metadata
- Authors
- Binneman, B., Feltner, D., Kolluri, S., Shi, Y., Qiu, R., & Stiger, T.
- Affiliations
- Pfizer (United States) (US)
- ORCID
- Qiu, Ruolun
- Venue
- American Journal of Psychiatry
- Published
- 2008-05
- Volume
- 165
- Issue
- 5
- Pages
- 617-620
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2129752568
- Cited by
- 254
- References
- 13
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 10 · 2023: 6 · 2022: 9 · 2021: 7 · 2020: 7 · 2019: 13 · 2018: 10 · 2017: 8 · 2016: 19 · 2015: 13 · 2014: 14 · 2013: 16 · 2012: 21
- FWCI
- 22.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- corticotropin-releasing factor, major depressive disorder, recurrent depression, sertraline, antidepressant efficacy, drug safety and tolerability, futility, interim analysis, group sequential designs
- MeSH terms
- CRF Receptor, Type 1, Adult, Aged, Antidepressive Agents, Major Depressive Disorder, Double-Blind Method, Humans, Middle Aged, Surveys and Questionnaires, Treatment Outcome, Receptors, Corticotropin-Releasing Hormone, Sertraline
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.